+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Diabetes Associated Ophthalmic Treatment Market Research Report by Product Type (Devices and Drugs), Application, End-use, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 253 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5716081
UP TO OFF until Mar 31st 2023
The Global Diabetes Associated Ophthalmic Treatment Market size was estimated at USD 5,291.23 million in 2022, USD 5,718.23 million in 2023, and is projected to grow at a CAGR of 8.52% to reach USD 10,182.06 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Diabetes Associated Ophthalmic Treatment Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Diabetes Associated Ophthalmic Treatment Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Diabetes Associated Ophthalmic Treatment Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Diabetes Associated Ophthalmic Treatment Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Diabetes Associated Ophthalmic Treatment Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Product Type, the market is studied across Devices and Drugs.
  • Based on Application, the market is studied across Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye Syndrome, Eye Allergy & Infection, Glaucoma, and Uveitis.
  • Based on End-use, the market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Centers.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Diabetes Associated Ophthalmic Treatment Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Diabetes Associated Ophthalmic Treatment Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Diabetes Associated Ophthalmic Treatment Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Diabetes Associated Ophthalmic Treatment Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Diabetes Associated Ophthalmic Treatment Market, including Adverum Biotechnologies, Inc., Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Apexian Pharmaceuticals, Inc., Bausch & Lomb Incorporated., Bayer AG, Eisai Co Ltd., Graybug Vision Inc., Kalvista Pharmaceuticals Ltd., Kodiak Sciences Inc., Kubota Vision Inc., Novartis AG, Ocuphire Pharma, Inc., and Regeneron Pharmaceuticals Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetes Associated Ophthalmic Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Associated Ophthalmic Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Associated Ophthalmic Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Diabetes Associated Ophthalmic Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Diabetes Associated Ophthalmic Treatment Market?
6. What is the market share of the leading vendors in the Global Diabetes Associated Ophthalmic Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Diabetes Associated Ophthalmic Treatment Market?
Frequently Asked Questions about the Global Diabetes Associated Ophthalmic Treatment Market

What is the estimated value of the Global Diabetes Associated Ophthalmic Treatment Market?

The Global Diabetes Associated Ophthalmic Treatment Market was estimated to be valued at $5291.23 Million in 2022.

What is the growth rate of the Global Diabetes Associated Ophthalmic Treatment Market?

The growth rate of the Global Diabetes Associated Ophthalmic Treatment Market is 8.5%, with an estimated value of $10182.06 Million by 2030.

What is the forecasted size of the Global Diabetes Associated Ophthalmic Treatment Market?

The Global Diabetes Associated Ophthalmic Treatment Market is estimated to be worth $10182.06 Million by 2030.

Who are the key companies in the Global Diabetes Associated Ophthalmic Treatment Market?

Key companies in the Global Diabetes Associated Ophthalmic Treatment Market include Adverum Biotechnologies, Inc., Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Apexian Pharmaceuticals, Inc., Bausch & Lomb Incorporated., Bayer AG, Eisai Co Ltd. and Kalvista Pharmaceuticals Ltd..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of diabetes with rising geriatric population
5.1.1.2. Growing inclination towards early diagnosis of diabetes
5.1.1.3. Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
5.1.2. Restraints
5.1.2.1. Lack of skilled and knowledgeable ophthalmologists
5.1.3. Opportunities
5.1.3.1. Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
5.1.3.2. High potential for diabetes associated ophthalmic treatment devices
5.1.4. Challenges
5.1.4.1. Long duration of drug approvals for diabetes associated ophthalmic treatment
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Diabetes Associated Ophthalmic Treatment Market, by Product Type
6.1. Introduction
6.2. Devices
6.3. Drugs

7. Diabetes Associated Ophthalmic Treatment Market, by Application
7.1. Introduction
7.2. Cataract
7.3. Diabetic associated Macular Degeneration
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye Syndrome
7.7. Eye Allergy & Infection
7.8. Glaucoma
7.9. Uveitis

8. Diabetes Associated Ophthalmic Treatment Market, by End-use
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Ophthalmic Centers

9. Americas Diabetes Associated Ophthalmic Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Adverum Biotechnologies, Inc.
13.2. Alimera Sciences, Inc.
13.3. Allergan PLC
13.4. Ampio Pharmaceuticals, Inc.
13.5. Apexian Pharmaceuticals, Inc.
13.6. Bausch & Lomb Incorporated.
13.7. Bayer AG
13.8. Eisai Co Ltd.
13.9. Graybug Vision Inc.
13.10. Kalvista Pharmaceuticals Ltd.
13.11. Kodiak Sciences Inc.
13.12. Kubota Vision Inc.
13.13. Novartis AG
13.14. Ocuphire Pharma, Inc.
13.15. Regeneron Pharmaceuticals Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET DYNAMICS
FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT TYPE, 2030
FIGURE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, 2018-2030 (USD MILLION)
FIGURE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, 2018-2030 (USD MILLION)
FIGURE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2022 VS 2030 (%)
FIGURE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USE, 2030
FIGURE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
FIGURE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
FIGURE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, 2018-2030 (USD MILLION)
FIGURE 34. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 36. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 37. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 38. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 44. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 45. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 46. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 48. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 49. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 50. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 64. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 66. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 86. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 87. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 88. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 89. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 61. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 62. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 83. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 87. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 95. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 96. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 140. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 144. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 156. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 157. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 168. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 169. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 172. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 173. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 176. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 177. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 192. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 193. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 204. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 205. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 216. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 217. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 218. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 219. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RANKING, BY KEY PLAYER, 2022
TABLE 220. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 221. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 222. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET MERGER & ACQUISITION
TABLE 223. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 224. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 225. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET INVESTMENT & FUNDING
TABLE 226. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 227. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Adverum Biotechnologies, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated.
  • Bayer AG
  • Eisai Co Ltd.
  • Graybug Vision Inc.
  • Kalvista Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Kubota Vision Inc.
  • Novartis AG
  • Ocuphire Pharma, Inc.
  • Regeneron Pharmaceuticals Inc.

Methodology

Loading
LOADING...